Data as of Oct 28, 2026.

vsCompare their flowsaskIQ about these two fundsAsk the committee about these two funds
Across categories

IBB vs XOVR: Differences, Returns & Fees

Share
Share on XDownload as PDF

Over the year to Oct 28, 2026, IBB returned +37.5% to XOVR's −3.0%, and IBB charges 0.44% to XOVR's 1.81%.

askIQ about this page

askIQ about IBB and XOVR

Net assets: $11.0bn on Oct 27, 2026 for iShares Biotechnology ETF, and $2.2bn on Jun 30, 2026 for ERShares Private-Public Crossover ETF.

At a glance
+37.5%
IBB total return, 1 year
−3.0%
XOVR total return, 1 year
0.44%
IBB expense ratio
1.81%
XOVR expense ratio

Pair scorecard

IBB costs 1.37 points a year less; their one-year returns differ by 40.5 points.

IBB vs XOVR: Differences, Returns & Fees
MeasureIBBXOVR
Return
Total return, 1 year+37.5%−3.0%
Drawdown
Below its high6.5%, high on Oct 5, 2026
Benchmark
What it tracksBiotechNo index, actively managed
Cost and size
Expense ratio0.44%1.81%
Net assets, IBB as of Oct 27, 2026 and XOVR as of Jun 30, 2026$11.0bn$2.2bn
Active share vs the S&P 50099%
Holdings
Holdings in common6%
Top ten holdings, share of the fund50%63.1%

Holdings in common uses holdings dated Jun 30, 2026 and Oct 27, 2026. Method

What they share

6%

By the books each fund has filed, IBB and XOVR hold 6% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Oct 27, 2026.

0 half 100%

half

6% in common

Positions both hold · largest shared weight first IBB XOVR
NATERA 3.85% 3.70%
EXELIXIS INC 1.09% 1.89%
MEDPACE HOLDINGS 1.06% 1.67%
TEMPUS AI CLASS A 0.54% 2.05%
Only in one fund ↓
Only in IBB
GILEAD SCIENCES 8.56%
AMGEN INC 8.20%
VERTEX PHARMACEUTICALS 7.53%
REGENERON PHARMACEUTICALS 5.64%
MODERNA 5.29%
ARGENX SE ADR 3.42%
ILLUMINA INC 2.93%
BIOGEN 2.58%
Only in XOVR
N/A 17.73%
Nvidia Corp 9.47%
Astera Labs Inc 7.75%
Alphabet Inc 6.52%
Meta Platforms Inc 4.47%
Applovin Corp 3.95%
Robinhood Markets Inc 3.55%
Veeva Systems Inc 3.17%
Check overlap with more funds →

Side by side

IBB iShares Biotechnology ETF XOVR ERShares Private-Public Crossover ETF
Where it sits Thematic ETF Stock ETF
Issuer iShares ERShares
What it is Biotech Actively managed
Total return, 1 year +37.5% −3.0%
Expense ratio 0.44% 1.81%
Already in the S&P 500 40.2% 43.4%
Holdings 245 32
Net assets, IBB as of Oct 27, 2026 and XOVR as of Jun 30, 2026 $11.0bn $2.2bn

IBB and XOVR on the fields both publish, as of Oct 28, 2026. Source: ETFIQ.

Alert

IBB flows, by email on Sundays.

One-click unsubscribe. See Privacy.

About each fund
IBB

By weight, 40% of IBB's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 50% of the fund across 245 positions, as published by its issuer for Oct 27, 2026. Over the year to Oct 28, 2026 the fund returned +37.5% with distributions reinvested.

XOVR

XOVR is actively managed and tracks no index. Over the year to Oct 28, 2026 it returned −3.0% with distributions reinvested. The prospectus expense ratio is 1.81% a year. By its holdings filed for Jun 30, 2026, 43% of the fund by weight is stocks the S&P 500 also holds, across 32 positions, with the top ten at 63.1%. It sat 6.5% below its high of Oct 5, 2026 on Oct 28, 2026.

Questions people ask

Are IBB and XOVR in the same category?
IBB is a thematic ETF and XOVR is a stock ETF, so they do different jobs. The table compares what both publish: return, cost and holdings.
Which returned more over the last year, IBB or XOVR?
In the year to Oct 28, 2026, with distributions reinvested, IBB returned +37.5% and XOVR −3.0%.
Which is cheaper, IBB or XOVR?
IBB is cheaper, by 1.37 percentage points a year. That is about $137 on $10,000 held for a year. Fees come from each fund's prospectus.
How much do IBB and XOVR overlap with the S&P 500?
By their latest filed holdings, 40% of IBB and 43% of XOVR by weight is stocks the S&P 500 already holds.
Other comparisons
Cite this pageCitation, APA and Markdown

ETFIQ, IBB against XOVR, data as of Oct 28, 2026. https://etfiq.com/compare/any/ibb-vs-xovr

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.